N,N,5-trimethylheptan-2-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N,5-trimethylheptan-2-amine
• 化学式: C₁₀H₂₃N
• 分子量: 157.3
• InChiKey: IKUITVCLHAPFSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Lithium-doped pernigraniline-based materials
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US10651473B2

  公开（公告）日：2020-05-12

  The present invention relates to a new lithium-doped Pernigraniline-based material, a method for the preparation thereof, its use in various applications, an electrode comprising said lithium-doped Pernigraniline-based material and its preparation method, a membrane comprising said lithium-doped Pernigraniline-based material and its preparation method, and an electrochemical storage system comprising said electrode.

  本发明涉及一种新型掺锂芘基材料、其制备方法、其在各种应用中的用途、包含所述掺锂芘基材料及其制备方法的电极、包含所述掺锂芘基材料及其制备方法的膜，以及包含所述电极的电化学存储系统。
• New lithium-doped Pernigraniline-based materials
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US20190036123A1

  公开（公告）日：2019-01-31

  The present invention relates to a new lithium-doped Pernigraniline-based material, a method for the preparation thereof, its use in various applications, an electrode comprising said lithium-doped Pernigraniline-based material and its preparation method, a membrane comprising said lithium-doped Pernigraniline-based material and its preparation method, and an electrochemical storage system comprising said electrode.
• INTRAOCULAR IMPLANTS AND RELATED KITS AND METHODS
  申请人：Sight Sciences, Inc.

  公开号：US20220168146A1

  公开（公告）日：2022-06-02

  Devices, methods and kits are described for reducing intraocular pressure. The devices include a support that is implantable within Schlemm's canal and that may restore or maintain at least partial patency of the canal without substantially interfering with transmural or transluminal fluid flow across the canal. The devices utilize the natural drainage process of the eye and may be implanted with minimal trauma to the eye. Kits may include a support and an introducer for implanting the support within Schlemm's canal. Methods may include implanting a support within Schlemm's canal, where the support is capable of restoring or maintaining at least partial patency of the canal without substantial interference with transmural or transluminal fluid flow across the canal.